0
0
A recent study has raised concerns over the cardiovascular safety of glipizide, a widely prescribed medication for type 2 diabetes in the United States. The research, carried out by scientists from Mass General Brigham and published in JAMA Network Open, analyzed nationwide data covering nearly 50,000 patients who were treated with different medications from the sulfonylurea class.
According to the study, glipizide was linked to a significantly higher incidence of heart failure, related hospitalizations, and death compared to patients taking dipeptidyl peptidase-4 (DPP-4) inhibitors. The findings suggest a 13% increase in the risk of major adverse cardiovascular events in patients treated with glipizide alongside metformin, compared to those treated with DPP-4 inhibitors.
Dr. Alexander Turchin, the study’s corresponding author and a physician in the Division of Endocrinology at Brigham and Women’s Hospital, emphasized the importance of these findings for diabetes care. “While sulfonylureas are popular and affordable diabetes medications, there is a lack of long-term clinical data on how they affect cardiac health in comparison to more neutral alternatives,” he said.
The comprehensive research included 48,165 adults with type 2 diabetes and moderate cardiovascular risk, receiving care at 10 medical centers across the country. While other sulfonylureas such as glimepiride and glyburide showed smaller and less definitive effects, glipizide stood out for its stronger association with negative heart-related outcomes.
The authors highlighted the need to evaluate each medication within a drug class for its unique risks and called for more research to better understand the mechanisms behind these findings.
Disclaimer:
This article is for informational purposes only and is not a substitute for professional medical advice. Consult your healthcare provider before making any changes to your medication or treatment plan, especially if you have concerns regarding diabetes management or cardiovascular risk.
